StreetInsider.com News Articles

Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations

Wed, 26 Aug 2026 10:45:00 -0400

Lowest-ever Scope 1 and Scope 2 emissions mark a milestone year in the Company's SBTi-approved decarbonisation journey

Mumbai, India, Aug. 26, 2026 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceuticals company, today released its Sustainability Report 2025–26, showcasing significant progress across its environmental, social and governance (ESG) priorities. Anchored by the theme "Advancing Innovation, Leveraging Sustainability," the report highlights how sustainability continues to be integrated into the Company's strategy, operations and innovation agenda while creating long-term value for patients, customers, communities and stakeholders.

Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations

Wed, 26 Aug 2026 10:45:00 -0400

Lowest-ever Scope 1 and Scope 2 emissions mark a milestone year in the Company's SBTi-approved decarbonisation journey

Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations

Wed, 26 Aug 2026 10:45:00 -0400

Lowest-ever Scope 1 and Scope 2 emissions mark a milestone year in the Company's SBTi-approved decarbonisation journey

Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations

Wed, 26 Aug 2026 10:45:00 -0400

Lowest-ever Scope 1 and Scope 2 emissions mark a milestone year in the Company's SBTi-approved decarbonisation journey

Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations

Wed, 26 Aug 2026 10:45:00 -0400

Lowest-ever Scope 1 and Scope 2 emissions mark a milestone year in the Company's SBTi-approved decarbonisation journey

Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations

Wed, 26 Aug 2026 10:45:00 -0400

Lowest-ever Scope 1 and Scope 2 emissions mark a milestone year in the Company's SBTi-approved decarbonisation journey

Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations

Wed, 26 Aug 2026 10:45:00 -0400

Lowest-ever Scope 1 and Scope 2 emissions mark a milestone year in the Company's SBTi-approved decarbonisation journey

Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations

Wed, 26 Aug 2026 10:45:00 -0400

Lowest-ever Scope 1 and Scope 2 emissions mark a milestone year in the Company's SBTi-approved decarbonisation journey

Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations

Wed, 26 Aug 2026 10:45:00 -0400

Lowest-ever Scope 1 and Scope 2 emissions mark a milestone year in the Company's SBTi-approved decarbonisation journey

Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations

Wed, 26 Aug 2026 10:45:00 -0400

Lowest-ever Scope 1 and Scope 2 emissions mark a milestone year in the Company's SBTi-approved decarbonisation journey

Piramal Pharma acquires majority stake in Yapan Bio for $7.95M

Tue, 18 Aug 2026 15:37:45 -0400

Piramal Pharma Ltd. (NSE: PPLPHARMA, BSE: 543635) has completed the acquisition of an additional 40.67% stake in Yapan Bio Private Limited, a Hyderabad-based contract development and manufacturing organization (CDMO) specializing in vaccines and biologics, for ₹76 crore ($7.95 million).

The transaction, finalized on Aug. 18, 2026, brings Piramal Pharma's total ownership in Yapan Bio to 74%, converting the company from an associate to a subsidiary. Piramal Pharma had first acquired a stake in Yapan Bio in 2021.

Yapan Bio specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics. The subsidiary will continue to operate

Piramal Pharma acquires majority stake in Yapan Bio for $7.95M

Tue, 18 Aug 2026 15:37:45 -0400

Yapan Bio specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics. The subsidiary will continue to operate

Piramal Pharma acquires majority stake in Yapan Bio for $7.95M

Tue, 18 Aug 2026 15:37:45 -0400

Yapan Bio specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics. The subsidiary will continue to operate

Piramal Pharma acquires majority stake in Yapan Bio for $7.95M

Tue, 18 Aug 2026 15:37:45 -0400

Yapan Bio specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics. The subsidiary will continue to operate

Piramal Pharma acquires majority stake in Yapan Bio for $7.95M

Tue, 18 Aug 2026 15:37:45 -0400

Yapan Bio specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics. The subsidiary will continue to operate

Piramal Pharma acquires majority stake in Yapan Bio for $7.95M

Tue, 18 Aug 2026 15:37:45 -0400

Yapan Bio specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics. The subsidiary will continue to operate

Piramal Pharma acquires majority stake in Yapan Bio for $7.95M

Tue, 18 Aug 2026 15:37:45 -0400

Yapan Bio specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics. The subsidiary will continue to operate

Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited

Tue, 18 Aug 2026 15:36:00 -0400

Yapan Bio Private Limited specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics.
Piramal has held a stake in Yapan Bio since 2021, enabling the Company to provide a broad range of capabilities across biologics development and manufacturing.
This acquisition transforms Yapan Bio from Piramal's associate company to its subsidiary, enhancing the Company's ability to offer complex, integrated large molecule CDMO services.

MUMBAI, India, Aug. 18, 2026 /PRNewswire/ -- Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) ("PPL) has completed the acquisition

Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited

Tue, 18 Aug 2026 15:36:00 -0400

Yapan Bio Private Limited specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics.
Piramal has held a stake in Yapan Bio since 2021, enabling the Company to provide a broad range of capabilities across biologics development and manufacturing.
This acquisition transforms Yapan Bio from Piramal's associate company to its subsidiary, enhancing the Company's ability to offer complex, integrated large molecule CDMO services.

MUMBAI, India, Aug. 18, 2026 /PRNewswire/ -- Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) ("PPL) has completed the acquisition

Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited

Tue, 18 Aug 2026 15:36:00 -0400

Yapan Bio Private Limited specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics.
Piramal has held a stake in Yapan Bio since 2021, enabling the Company to provide a broad range of capabilities across biologics development and manufacturing.
This acquisition transforms Yapan Bio from Piramal's associate company to its subsidiary, enhancing the Company's ability to offer complex, integrated large molecule CDMO services.

MUMBAI, India, Aug. 18, 2026 /PRNewswire/ -- Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) ("PPL) has completed the acquisition

Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited

Tue, 18 Aug 2026 15:36:00 -0400

Yapan Bio Private Limited specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics.
Piramal has held a stake in Yapan Bio since 2021, enabling the Company to provide a broad range of capabilities across biologics development and manufacturing.
This acquisition transforms Yapan Bio from Piramal's associate company to its subsidiary, enhancing the Company's ability to offer complex, integrated large molecule CDMO services.

MUMBAI, India, Aug. 18, 2026 /PRNewswire/ -- Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) ("PPL) has completed the acquisition

Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited

Tue, 18 Aug 2026 15:36:00 -0400

Yapan Bio Private Limited specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics.
Piramal has held a stake in Yapan Bio since 2021, enabling the Company to provide a broad range of capabilities across biologics development and manufacturing.
This acquisition transforms Yapan Bio from Piramal's associate company to its subsidiary, enhancing the Company's ability to offer complex, integrated large molecule CDMO services.

MUMBAI, India, Aug. 18, 2026 /PRNewswire/ -- Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) ("PPL) has completed the acquisition

Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited

Tue, 18 Aug 2026 15:36:00 -0400

Yapan Bio Private Limited specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics.
Piramal has held a stake in Yapan Bio since 2021, enabling the Company to provide a broad range of capabilities across biologics development and manufacturing.
This acquisition transforms Yapan Bio from Piramal's associate company to its subsidiary, enhancing the Company's ability to offer complex, integrated large molecule CDMO services.

MUMBAI, India, Aug. 18, 2026 /PRNewswire/ -- Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) ("PPL) has completed the acquisition

Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited

Tue, 18 Aug 2026 15:36:00 -0400

Yapan Bio Private Limited specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics.
Piramal has held a stake in Yapan Bio since 2021, enabling the Company to provide a broad range of capabilities across biologics development and manufacturing.
This acquisition transforms Yapan Bio from Piramal's associate company to its subsidiary, enhancing the Company's ability to offer complex, integrated large molecule CDMO services.

MUMBAI, India, Aug. 18, 2026 /PRNewswire/ -- Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) ("PPL) has completed the acquisition

Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited

Tue, 18 Aug 2026 15:36:00 -0400

Yapan Bio Private Limited specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics.
Piramal has held a stake in Yapan Bio since 2021, enabling the Company to provide a broad range of capabilities across biologics development and manufacturing.
This acquisition transforms Yapan Bio from Piramal's associate company to its subsidiary, enhancing the Company's ability to offer complex, integrated large molecule CDMO services.

MUMBAI, India, Aug. 18, 2026 /PRNewswire/ -- Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) ("PPL) has completed the acquisition